Today’s selection covers a targeted genetic strategy for Rett syndrome, a critical re-evaluation of the "autism spectrum" definition, and the specific FDA approval of leucovorin for genetic folate deficiencies. (Blog Name: Living on the Spectrum).
Exon-skipping approach boosts levels of key Rett syndrome protein
Research Findings
Researchers developed a genetic method called exon-skipping to increase MECP2 protein levels, which are typically deficient in Rett syndrome. The strategy uses an antisense oligonucleotide to bias protein production toward the "e1" version of MECP2. This version translates more efficiently than the "e2" version, successfully raising protein levels in mice and human-derived neurons.
Applicable Population
This approach targets the estimated 65% of individuals with Rett syndrome who retain some residual protein function. By optimizing the production of existing proteins rather than introducing new genes, the method partially corrected cellular hallmarks of the condition in laboratory settings.
Significance & Limitations
While the results in cellular models are promising, the research team must validate these findings in established Rett syndrome animal models. Clinical trials remain a future step, as experts require further evidence of safety and efficacy in complex living systems before human testing.
Uta Frith: Why I no longer think autism is a spectrum
Redefining Subgroups
Dame Uta Frith argues that the "autism spectrum" has become too broad to remain a useful medical diagnosis. She proposes distinguishing between two distinct groups: children diagnosed early who often have intellectual disabilities, and a growing group of adolescents and women diagnosed later who primarily experience social anxiety and hypersensitivity. Frith maintains that autism is a neurodevelopmental disorder rooted in complex genetics involving hundreds of genes.
Clinical Perspectives
Frith questions the scientific basis of "masking" and suggests that diagnostic assessments rely too much on subjective interviews. She advocates for a return to objective clinical observations of social reciprocity. Additionally, she expresses skepticism regarding sensory adjustments like ear defenders, noting a lack of evidence for their long-term benefits.
Educational Practices
For students with high language abilities, Frith recommends that teachers provide concrete, literal instructions. For the "hypersensitive" group, the focus should shift toward building trust and resilience rather than just accommodating sensitivities. These practices aim to address specific cognitive needs rather than applying a one-size-fits-all spectrum approach.
Analyzing the evidence base for leucovorin as an autism treatment
Targeted FDA Approval
The FDA expanded the label for leucovorin to treat autism symptoms specifically in individuals with cerebral folate deficiency (CFD) caused by FOLR1 gene variants. The decision rests on 23 studies involving 46 patients where brain folate levels were low despite normal blood levels. In this specific genetic group, the treatment normalized brain folate, reduced seizures, and improved social communication.
Scientific Controversies
Autism experts caution that this approval does not apply to the general autistic population. Some researchers describe the "autoimmune CFD" hypothesis—the idea that folate receptor antibodies cause general autism—as an unproven construct based on weak data. The FDA clarified that leucovorin is not a general treatment for autism but a targeted intervention for a rare genetic condition.
Potential Risks
Clinicians warn that broad off-label use could lead to drug shortages for patients who strictly require the medication. Families seeking the drug without a CFD diagnosis may also expose children to unnecessary side effects, such as gastrointestinal distress, without evidence of behavioral benefit.
Podcast Transcript
Aaron: Hello everyone, welcome to the podcast. I am Aaron.
Jamie: Hello everyone, I am Jamie.
Aaron: In this episode, we have organized some recent content related to Autism, ADHD, SPD, DLD, and related neurodevelopmental differences. Some are research-based, and some are discussions from the community. After looking through them, there are a few points I really want to chat with you about.
Jamie: Yes, I have a similar feeling. Some content doesn't look complex at first glance, but if you really follow the thought process, it's worth talking about slowly.
Aaron: Then let's start with one of them. Jamie, I saw a study recently about Rett syndrome and something called exon-skipping. For those who might not know, Rett syndrome often overlaps with autism. I was trying to wrap my head around it, but the science felt a bit heavy. What exactly are they trying to do with this protein levels thing?
Jamie: It is a bit technical, but the core idea is actually quite clever. Rett syndrome is usually caused by a deficiency in a protein called MECP2. Our bodies actually make two versions of this protein, called e1 and e2. This research found that the e1 version is much more efficient—it’s easier for our cells to "translate" or build. By using a specific genetic tool, they essentially nudged the cells to ignore the instructions for the less efficient version and focus on making more of the e1 version.
Aaron: Okay, so it’s like if you have a factory making two types of the same product, but one is much faster to produce, so you just tell the assembly line to skip the slow one and focus on the fast one to boost the total stock?
Jamie: That’s a great way to visualize it. In their tests with mice and human-derived neurons, it actually helped correct some of the cellular issues we see in Rett syndrome. It’s particularly interesting because it could potentially help the roughly 65% of people with Rett syndrome who still have some residual protein function.
Aaron: That sounds like a significant number of people who could see an impact. But I noticed this is still in the "mice and neurons" stage. From a parent's perspective, I’m always wondering, how far away are we from this being something a child could actually receive?
Jamie: That’s the vital question. The researchers are very clear that they need to validate this in more established animal models before even thinking about clinical trials. It’s a promising biological "proof of concept," but moving from a dish of cells to a human brain is a massive leap with many safety hurdles.
Aaron: It’s a good reminder to stay hopeful but patient. Speaking of how we define and treat these conditions, I came across some pretty bold statements from Dame Uta Frith. She’s a huge name in this field, but she seems to be suggesting that the "autism spectrum" as we know it might be expanding so much that the diagnosis is starting to lose its meaning. That feels like a big shift in how we think about things.
Jamie: It really is. Frith is a pioneer, and her concern is that we are grouping very different experiences under one single umbrella. She suggests we should perhaps distinguish between two main groups: children diagnosed early who often have intellectual disabilities, and then this newer, fast-growing group—often adolescents and women—who primarily experience social anxiety and hypersensitivity.
Aaron: I can see why she’d say that, but she also touched on "masking," which is a word we hear everywhere now. She seemed skeptical of it, saying it lacks a scientific basis. I have to say, that might be hard for a lot of people to hear, especially those who feel they spend their whole lives trying to fit in.
Jamie: I think her perspective comes from a desire for objective clinical observation. She’s worried that we are relying too much on what people report in interviews rather than what can be measured or observed in social reciprocity. It’s a tension between the lived experience of the individual and the traditional medical model that looks for external, measurable "signs."
Aaron: And she also mentioned sensory adjustments, like ear defenders. I know so many families who rely on those. Her take was that there isn’t enough long-term evidence to show they actually help the child's development. It’s one of those things where a parent thinks, "but it helps my child stay calm right now," while a researcher is looking at what happens five years down the road.
Jamie: Exactly. It’s not necessarily saying "don't use them," but rather pointing out that we don't have the data yet to say they are a therapeutic benefit in the long run. It’s about being honest about the uncertainty of our current tools.
Aaron: That honesty about uncertainty actually leads nicely into some news from the FDA. They recently expanded the label for a drug called leucovorin for a very specific type of autism symptom. When people hear "FDA approves drug for autism," it usually causes a huge stir. But as I understand it, this isn't for everyone, right?
Jamie: Right, and that distinction is crucial. It’s specifically for individuals who have Cerebral Folate Deficiency, or CFD, caused by a mutation in the FOLR1 gene. This is a very rare condition where folate can’t get into the brain properly, even if blood levels are normal. In those specific cases, the drug can normalize brain folate and improve social and communication skills.
Aaron: So it’s a very targeted fix for a genetic issue. But I saw that experts are worried this might lead to "off-label" use. Basically, parents might try to get it for their kids even if they don't have this rare genetic condition, thinking it’s a general treatment for autism.
Jamie: That’s the big concern. There is this "autoimmune CFD" hypothesis floating around, suggesting that antibodies against folate receptors might cause autism symptoms in a broader group, but many researchers feel that evidence is quite weak right now. If parents start seeking this drug off-label, it could lead to shortages for the people who actually need it for the genetic condition, not to mention potential side effects like gastrointestinal issues for kids who might not benefit from it at all.
Aaron: It feels like a recurring theme today: the gap between a very specific scientific discovery and the way the public might want to apply it to everyone. It’s that balance between wanting a solution now and making sure the science actually supports that specific person.
Jamie: It really is. Whether it’s gene therapy, how we define the spectrum, or new medications, these findings remind us that "autism" isn't one single thing with one single answer. It’s a complex landscape where individual differences matter more than the label itself.
Aaron: Well, that’s a lot to process, but I think it helps to look at these updates as pieces of a much larger puzzle we’re still putting together. Thank you for walking through the science with me, Jamie.
Jamie: Of course. It’s always good to look at the details behind the headlines.
Aaron: We’re going to wrap up here for today. If you’d like to dig deeper into the research papers or the articles we discussed, you can find all the summaries and original links on our episode page or our website. Thanks for listening, and we’ll talk to you next time.
Jamie: Goodbye everyone.